Sale!

Thymosin Beta-4 (TB500)

In stock

$32.98$39.99

Concentration
2 mg per vial
Purchase this product now and earn 33 Points!

This product is prepared for LABORATORY RESEARCH USE ONLY and may not be used for other purposes.

-
+

Free & Fast
Shipping

Earn
Rewards

Excellent
Service

Properties

Molecular Formula C212H350N56O78S
Molecular Weight 4963
Monoisotopic Mass 4960.4863169
Polar Area 2250
Complexity 12200
XLogP -43.5
Heavy Atom Count 347
Hydrogen Bond Donor Count 72
Hydrogen Bond Acceptor Count 88
Rotatable Bond Count 180
Physical Appearance Fine White Lyophilized Powder
Stability Lyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS Thymosin Beta-4 (TB500) Laboratory Chemical Safety Summary

Identifiers

CID 45382195
CAS 77591-33-4
InChI InChI=1S/C212H350N56O78S/c1-16-106(7)166(261-190(323)131(64-75-160(292)293)231-172(305)109(10)228-174(307)134(78-91-347-15)245-196(329)140(98-165(302)303)255-201(334)147-53-39-88-266(147)209(342)135(52-29-38-87-221)250-197(330)139(97-164(300)301)254-198(331)143(100-269)229-113(14)276)204(337)246-129(62-73-158(288)289)187(320)233-118(47-24-33-82-216)179(312)252-137(94-114-42-19-18-20-43-114)194(327)253-138(96-163(298)299)195(328)237-121(50-27-36-85-219)181(314)258-144(101-270)199(332)239-119(48-25-34-83-217)178(311)251-136(92-104(3)4)193(326)236-116(45-22-31-80-214)175(308)235-122(51-28-37-86-220)189(322)263-168(110(11)273)207(340)249-133(66-77-162(296)297)192(325)264-169(111(12)274)206(339)248-126(58-69-152(224)279)184(317)243-128(61-72-157(286)287)186(319)234-120(49-26-35-84-218)180(313)256-142(95-153(225)280)211(344)268-90-40-54-148(268)202(335)257-141(93-105(5)6)210(343)267-89-41-55-149(267)203(336)259-145(102-271)200(333)238-117(46-23-32-81-215)177(310)244-132(65-76-161(294)295)191(324)265-170(112(13)275)208(341)262-167(107(8)17-2)205(338)247-130(63-74-159(290)291)188(321)241-125(57-68-151(223)278)183(316)242-127(60-71-156(284)285)185(318)232-115(44-21-30-79-213)176(309)240-124(56-67-150(222)277)173(306)227-108(9)171(304)226-99-154(281)230-123(59-70-155(282)283)182(315)260-146(103-272)212(345)346/h18-20, 42-43, 104-112, 115-149, 166-170, 269-275H, 16-17, 21-41, 44-103, 213-221H2, 1-15H3, (H2, 222, 277)(H2, 223, 278)(H2, 224, 279)(H2, 225, 280)(H, 226, 304)(H, 227, 306)(H, 228, 307)(H, 229, 276)(H, 230, 281)(H, 231, 305)(H, 232, 318)(H, 233, 320)(H, 234, 319)(H, 235, 308)(H, 236, 326)(H, 237, 328)(H, 238, 333)(H, 239, 332)(H, 240, 309)(H, 241, 321)(H, 242, 316)(H, 243, 317)(H, 244, 310)(H, 245, 329)(H, 246, 337)(H, 247, 338)(H, 248, 339)(H, 249, 340)(H, 250, 330)(H, 251, 311)(H, 252, 312)(H, 253, 327)(H, 254, 331)(H, 255, 334)(H, 256, 313)(H, 257, 335)(H, 258, 314)(H, 259, 336)(H, 260, 315)(H, 261, 323)(H, 262, 341)(H, 263, 322)(H, 264, 325)(H, 265, 324)(H, 282, 283)(H, 284, 285)(H, 286, 287)(H, 288, 289)(H, 290, 291)(H, 292, 293)(H, 294, 295)(H, 296, 297)(H, 298, 299)(H, 300, 301)(H, 302, 303)(H, 345, 346)
InChIKey UGPMCIBIHRSCBV-UHFFFAOYSA-N
Canonical SMILES CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N2CCCC2C(=O)NC(CC(C)C)C(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)NC(C(C)CC)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(C)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CC(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C
IUPAC Name 4-[[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[2-[[1-[2-[[2-[(2-acetamido-3-hydroxypropanoyl)amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoylamino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoylamino]acetyl]amino]-5-[(1-carboxy-2-hydroxyethyl)amino]-5-oxopentanoic acid

2D Structure

Generated by Extreme Peptide with Open Babel, version 2.3.1, http://openbabel.org (accessed June 28, 2022)

Thymosin Beta-4 (TB500) 2D molecular structure vector generated with oBabel

Description

TB-500 is a synthetic analogue to a naturally occurring protein present in most kinds of mammalian tissue1. TB-500 is an active mediating agent in cellular proliferation and differentiation processes2. Researchers have found that TB-500 is a potent promoter of wound healing3 and modulator of the inflammatory response of animal test subjects4. Through its action of regulating the production of actin, an important cellular component involved in structure and movement of all cells, TB-500 is an agent with a broad spectrum of beneficial capabilities.

Muscle Repair and Maintenance

TB-500 has been researched extensively in the areas of muscle and connective tissue repair5. TB-500 has been shown to stimulate the overproduction of regenerative fibers following injury, thereby speeding the process of recovery with minimal inflammation and residual scarification.

TB-500’s property of enhancing muscle growth in both healthy and damaged tissues has led to its application as an experimental therapeutic in animal test subjects with muscular dystrophy6. Regular administration of TB-500 allowed animal test subjects with muscular dystrophy to achieve much improved maintenance of muscle growth and development, even in the absence of important, naturally occurring proteins that usually guide this action.

TB500 has also been researched to be an aid in the healing of heart tissue following heart attack7 and as a very powerful agent for quickly healing skin abrasions. TB500’s angiogenic (blood vessel-forming) properties8 are responsible for its excellent application in these areas.

Synonyms:

Thymosin Beta 4; TB500


Peer-Reviewed Sources:

  1. Safer, D., Elzinga, M., & Nachmias, V. T. (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry, 266(7), 4029-4032. ↩︎
  2. Grant, D. S., Kinsella, J. L., Kibbey, M. C., LaFlamme, S., Burbelo, P. D., Goldstein, A. L., & Kleinman, H. K. (1995). Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. Journal of cell science, 108(12), 3685-3694. ↩︎
  3. Malinda, K. M., Sidhu, G. S., Mani, H., Banaudha, K., Maheshwari, R. K., Goldstein, A. L., & Kleinman, H. K. (1999). Thymosin β4 accelerates wound healing. Journal of investigative dermatology, 113(3), 364-368. ↩︎
  4. Sosne, G., Szliter, E. A., Barrett, R., Kernacki, K. A., Kleinman, H., & Hazlett, L. D. (2002). Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental eye research,74(2), 293-299. ↩︎
  5. Blain, E. J., Mason, D. J., & Duance, V. C. (2002). The effect of thymosin beta4 on articular cartilage chondrocyte matrix metalloproteinase expression. Biochemical Society Transactions, 30(Pt 6), 879-882. ↩︎
  6. Spurney, C. F., Cha, H. J., Sali, A., Pandey, G. S., Pistilli, E., Guerron, A. D., & Nagaraju, K. (2010). Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PloS one, 5(1), e8976. ↩︎
  7. Crockford, D. (2007). Development of thymosin β4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences, 1112(1), 385-395. ↩︎
  8. Smart, N., Rossdeutsch, A., & Riley, P. R. (2007). Thymosin β4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis, 10(4), 229-241. ↩︎

All literature, information, and data, provided on this website are for informational and educational purposes only.

Accurate research is our priority.

Same Day Shipping
We offer same day shipping on all orders of in stock items placed before 12:00pm EST.
Dedicated Service
Our team is readily available to assist with all of your customer service requests.
Free Shipping
We've got you covered! Free shipping is available on any order over $50.
Earn Rewards
Earn points every time you buy from us and use them towards future orders!
Extreme Peptide vial with logo and indicators